参考文献/References:
[1]Li LJ,Gong C,Zhao MH,et al.Role of interleukin-22 in inflammatory bowel disease[J].World J Gastroenterol,2014,20(48):18177-18188.
[2]Perriard G,Mathias A,Enz L,et al.Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes[J].J Neuroinflammation,2015,12(1):119.
[3]Witte E,Witte K,Warszawska K,et al.Interleukin-22:a cytokine produced by T,NK and NKT cell subsets,with importance in the innate immune defense and tissue protection[J].Cytokine Growth Factor Rev,2010,21(5):365-379.
[4]Wolk K,Kunz S,Witte E,et al.IL-22 increases the innate immunity of tissues[J]. Immunity,2004,21(2):241-254.
[5]Zheng Y,Li T.Interleukin-22,a potent target for treatment of non-autoimmune diseases[J].Hum Vaccin Immunother,2018,14(12): 2811-2819.
[6]Dudakov JA,Hanash AM,van den Brink MR.Interleukin-22:Immunobiology and pathology[J].Annu Rev Immunol,2015,33(1):747-785.
[7]Huber S,Gagliani N,Zenewicz LA.IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine[J].Nature,2012,491(7423):259-263.
[8]Xia Q,Xiang X,Patel S,et al.Characterisation of IL-22 and interferon-gamma-inducible chemokines in human carotid plaque[J].Int J Cardiol,2012,154(2):187-189.
[9]Gong F,Wu J,Zhou P,et al.Interleukin-22 might act as a double-edged sword in type 2 diabetes and coronary artery disease[J]. Mediators Inflamm,2016, 2016: 8254797.
[10]Lin Y,Wu B,Lu Z,et al.Circulating Th22 and Th9 levels in patients with acute coronary syndrome[J]. Mediators Inflamm,2013,2013:635672.
[11]Yang L,Zhang Y,Wang L,et al.Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22[J].J Hepatol,2010,53(2):339-347.
[12]Wang X,Ota N,Manzanillo P,et al.Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes[J].Nature,2014,514(7521):237-241.
[13]Rattik S,Hultman K,Rauch U,et al.IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice[J].Atherosclerosis, 2015, 242(2):506-514.
[14]Libby P,Aikawa M.Stabilization of atherosclerotic plaques:new mechanisms and clinical targets[J].Nat Med,2002,8(11):1257-1262.
[15]Kolls JK,McCray PB,Chan YR.Cytokine-mediated regulation of antimicrobial proteins[J].Nat Rev Immunol,2008,8(11):829-835 .
[16]Fatkhullina AR,Peshkova IO,Dzutsev A,et al.An interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis[J].Immunity,2018,49(5):1-15.
[17]Kennedy MA,Barrera GC,Nakamura K,et al.ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation[J]. Cell Metab,2005,1(2):121-131.
[18]Chellan B,Yan L,Sontag TJ,et al.IL-22 is induced by S100/calgranulin and impairs cholesterol efflux in macrophages by downregulating ABCG1[J].J Lipid Res,2013,55(3):443-454.
[19]Shen J,Fang Y,Zhu H,et al.Plasma interleukin-22 levels are associated with prediabetes and type 2 diabetes in the Han Chinese population[J].J Diabetes Investig, 2017,9(1):33-38.
[20]Hasnain SZ,Borg DJ,Harcourt BE,et al.Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress[J].Nat Med, 2014, 20(12):1417-1426.
[21]Ashcroft FM,Rorsman P.Diabetes mellitus and the beta cell:the last ten years[J]. Cell, 2012,148(6):1160-1171.
[22]Hasnain SZ,Prins JB,McGuckin MA.Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes[J].J Mol Endocrinol,2016,56(2):R33-R54.
[23]Hou R,Zhang J,Yin T,et al.Upregulation of PTEN by peroxynitrite contributes to cytokine-induced apoptosis in pancreatic β-cells[J].Apoptosis,2010,15(8):877-886.
[24]Hu M,Yang S,Yang L,et al.Interleukin-22 alleviated palmitate-induced endoplasmic reticulum stress in INS-1 cells through activation of autophagy[J].PLoS ONE,2016,11(1),e0146818.
[25]Hartmann P,Seebauer CT,Mazagova M,et al.Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity[J].Am J Physiol Gastrointest Liver Physiol,2016,310(5):G310-G322.
[26]Shang H,Sun J,Chen YQ.Clostridium butyricum CGMCC0313.1 modulates lipid profile, insulin resistance and colon homeostasis in obese mice[J].PLoS ONE, 2016,11(4),e0154373.
[27]Hu M,Lin H,Yang L,et al.Interleukin-22 restored mitochondrial damage and impaired glucose-stimulated insulin secretion through down-regulation of uncoupling protein-2 in INS-1 cells[J].J Biochem,2017,161(5):433-439.
[28]Herder C,Kannenberg JM,Carstensen-Kirberg M,et al.Serum levels of interleukin-22,cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study[J].Cardiovasc Diabetol,2017,16(1):17.
[29]Fabbrini E,Cella M,McCartney SA,et al.Association between specific adipose tissue CD4 + T- cell populations and insulin resistance in obese individuals[J]. Gastroenterology,2013,145(2):366-374.
[30]Dalmas E,Donath, MY.A role for interleukin-22 in the alleviation of metabolic syndrome[J].Nat Med,2014,20(12):1379-1381.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(9):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(9):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(9):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(9):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(9):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(9):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[9]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(9):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
[10]林春尧 刘晓辉.IL-33/ST2在冠心病中的研究进展[J].心血管病学进展,2020,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.007]
LIN Chunyao LIU Xiaohui.IL-33/ST2 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(9):128.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.007]